Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Alterity Therapeutics Ltd ADR is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative disorders. The company’s current research centers on diseases such as Parkinson’s disease and multiple system atrophy, with a pipeline built around small-molecule drug candidates designed to address underlying disease mechanisms. Its lead programs are aimed at reducing pathological protein aggregation, modulating excess labile iron, and supporting neuronal function in the brain. Alterity Therapeutics also develops biomarker and clinical-stage assets to better understand progression in neurodegenerative conditions. Headquartered in Melbourne, Australia, the company operates in the global pharmaceutical and biotechnology market, where it contributes to ongoing efforts in targeted treatments for complex brain disorders. As an ADR, Alterity Therapeutics Ltd provides U.S. investors access to the company’s ordinary shares through a listed depositary receipt structure.
$4.51
$0.05 (-1.10%)
EOD Aug 28, 2026
Negative free cash flow of -A$11M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
A$0.00
Net Income (TTM)
-A$12M
▲ +2.9% YoY
Op. Margin
—
ROIC
-37.70%
▲ +24.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-A$11M
▼ -38.8% YoY
Op. Cash Flow (TTM)
-A$11M
▼ -38.8% YoY
Net Debt
-A$41M
Net Cash Position
Cash & Equiv.
A$41M
Continue Research
Alterity Therapeutics (ATHE)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Alterity Therapeutics scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Alterity Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -37.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ATHE's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.